After being delayed due to the COVID-19 pandemic, the CNM-Au8 study has officially moved to the phase 3 trial, due to positive results in the phase 2 trial.
CNM-Au8 is an experimental oral therapy created by Clene Nanomedicine. This treatment is made up of a gold nanocrystal suspension, that is liquid, that enters patients' spinal cord and brain. This liquid is a bioenergetic nanocatalyst, and its goal is to repair neuron damage by catalyzing biocellular reactions.
The original phase 2 trial was originally halted early due to challenges during the COVID-19 pandemic. Originally, the experiment was supposed to consist of 150 participants, however, the pandemic limited this number to 73. While the study did end early due to the pandemic, due to the positive results in the phase 2 trial, the company chose to move onto phase 3 trials.
The biggest success of the phase 2 trial, however, seems to be the vision improvements brought along by CNM-Au8. All 73 participants of the trial had vision issues due to multiple sclerosis, and the data from the nearly year long study shows that patients treated with CNM-Au8 had improvements in their vision.
While CNM-Au8 isn’t finished testing, hopefully in the near future this therapy treatment can help many people with multiple sclerosis. For now, the phase 3 trial has to start, and hopefully, the trial will be successful.
Comments